Clinical Trials
850 trialsA Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
PEM-PRO
IRCCS San Raffaele
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
T-ALL-2024
Institute of Hematology & Blood Diseases Hospital, China
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
M.D. Anderson Cancer Center
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Rutgers, The State University of New Jersey
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
ADJUNCT
MedSIR
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
Institute of Hematology & Blood Diseases Hospital, China
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Vanderbilt-Ingram Cancer Center
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
HARMONY
Hoosier Cancer Research Network
ECLAT
Memorial Sloan Kettering Cancer Center
MONAMI
Assistance Publique - Hôpitaux de Paris
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
INDIGO
Gustave Roussy, Cancer Campus, Grand Paris
OZM-034
University Health Network, Toronto
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
M.D. Anderson Cancer Center
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rutgers, The State University of New Jersey
A Study of ONC201 for Refractory Meningioma
University of Nebraska
PULSAR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
BEMAFLOT
Institut Cancerologie de l'Ouest
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Massachusetts General Hospital
CaptAin
Imperial College London
IMpALA
The Christie NHS Foundation Trust
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
West China Hospital
PRISM
Weill Medical College of Cornell University
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
UNC Lineberger Comprehensive Cancer Center
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
M.D. Anderson Cancer Center
REPRESENTATION
Latin American Cooperative Oncology Group
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
NANOPRO
Centre Francois Baclesse
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
M.D. Anderson Cancer Center
Neo-Kan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BIB 01
Institut Bergonié
EMPIRE
Institut Bergonié
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Stanford University
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
M.D. Anderson Cancer Center
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
Abemaciclib + Pembrolizumab In Glioblastoma
Dana-Farber Cancer Institute
TUXEDO-5
MedSIR
PRIMUS006
University of Glasgow
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Indiana University